Reversal of retinal pigment epithelial detachment after cessation of topical travoprost therapy
ConclusionHence, clinicians should be aware of this rare incidence of RPED followed by travoprost therapy. First case of RPED following travoprost therapy and complete reattachment upon withdrawal is reported here in this case report. (Source: International Ophthalmology)
Source: International Ophthalmology - March 22, 2018 Category: Opthalmology Source Type: research
Prospective Evaluation of Two iStent ® Trabecular Stents, One iStent Supra ® Suprachoroidal Stent, and Postoperative Prostaglandin in Refractory Glaucoma: 4-year Outcomes
ConclusionIOP control was achieved safely with two trabecular micro-bypass stents, one suprachoroidal stent, and postoperative prostaglandin. This microinvasive, ab interno approach introduces a possible new treatment option for refractory disease.Trial RegistrationNCT01456390.FundingGlaukos Corporation. (Source: Advances in Therapy)
Source: Advances in Therapy - February 23, 2018 Category: Drugs & Pharmacology Source Type: research
Periorbital Changes associated with Topical Prostaglandins Analogues in a Hispanic Population.
CONCLUSION: QOL questionnaire showed that Bimatoprost side effects had the most negative impact in QOL, followed by the Latanoprost and Travoprost groups.
PMID: 29220066 [PubMed - in process] (Source: Puerto Rico Health Sciences Journal)
Source: Puerto Rico Health Sciences Journal - December 9, 2017 Category: International Medicine & Public Health Tags: P R Health Sci J Source Type: research
A 3-month safety and efficacy study of travoprost 0.004% ophthalmic solution compared with timolol in pediatric patients with glaucoma or ocular hypertension
Conclusions This study found travoprost to be noninferior to timolol in lowering IOP in patients with pediatric glaucoma or ocular hypertension. Travoprost was well-tolerated, and no treatment-related systemic adverse events were reported. (Source: Journal of American Association for Pediatric Ophthalmology and Strabismus)
Source: Journal of American Association for Pediatric Ophthalmology and Strabismus - September 6, 2017 Category: Opthalmology Source Type: research
A 3-month safety and efficacy study of travoprost 0.004% ophthalmic solution compared with timolol in pediatric patients with glaucoma or ocular hypertension
To evaluate efficacy and safety of travoprost in pediatric patients with ocular hypertension or glaucoma and demonstrate its noninferiority to timolol. (Source: Journal of AAPOS)
Source: Journal of AAPOS - September 5, 2017 Category: Opthalmology Authors: El Roy Dixon, Theresa Landry, Subha Venkataraman, Nancy Gustafson, Craig Salem, Yasmin Bradfield, Leyla Ali Aljasim, Robert Feldman Source Type: research
Inadvertent Cyclodialysis Cleft and Hypotony Following Ab-Interno Trabeculotomy Using the Trabectome Device Requiring Surgical Repair
Conclusions: Inadvertent cyclodialysis cleft from a malpositioned AIT and resultant hypotony is rare and in this case was successfully treated by direct suture cyclopexy. (Source: Journal of Glaucoma)
Source: Journal of Glaucoma - August 1, 2017 Category: Opthalmology Tags: Case Report/Small Case Series Source Type: research
The efficacy and safety of bimatoprost/timolol maleate, latanoprost/timolol maleate, and travoprost/timolol maleate fixed combinations on 24-h IOP
ConclusionAll three fixed combinations effectively controlled IOP for 24-h and had a similar effect on diurnal and nocturnal IOP variations. (Source: International Ophthalmology)
Source: International Ophthalmology - June 14, 2017 Category: Opthalmology Source Type: research
Travoprost/timolol
(Source: Reactions Weekly)
Source: Reactions Weekly - June 1, 2017 Category: Drugs & Pharmacology Source Type: research
Blood Pressure Elevation Associated with Topical Prostaglandin F2 α Analogs: An Analysis of the Different Spontaneous Adverse Event Report Databases.
The objective of this study was to evaluate the association between topical PGF2α analogs and blood pressure elevation. We analyzed the reports obtained from the Food and Drug Administration Adverse Event Reporting System (FAERS) database from the first quarter of 2004 until the end of 2015 and the Japanese Adverse Drug Event Report (JADER) database from April 2004 to January 2016 for signal detection using reporting odds ratio (ROR), a method of disproportionality analyses. Signals are considered significant if the ROR estimates and lower bound of the 95% confidence interval (CI) exceed 1. Preferred terms in the Medical ...
Source: Biological and Pharmaceutical Bulletin - May 2, 2017 Category: Drugs & Pharmacology Authors: Ohyama K, Kawakami H, Inoue M Tags: Biol Pharm Bull Source Type: research
Implantation of two second ‐generation trabecular micro‐bypass stents and topical travoprost in open‐angle glaucoma not controlled on two preoperative medications: 18‐month follow‐up
Conclusions and RelevanceIn OAG eyes on 2 preoperative medications, treatment with 2 second‐generation trabecular stents and 1 postoperative prostaglandin resulted in mean IOP ≤13 mmHg with reduction of 1 medication, with favorable safety. These findings show the utility of second‐generation trabecular bypass with postoperative prostaglandin in patients with OAG. (Source: Clinical and Experimental Ophthalmology)
Source: Clinical and Experimental Ophthalmology - April 1, 2017 Category: Opthalmology Authors: John Berdahl, Lilit Voskanyan, Jonathan S Myers, Dana M Hornbeak, Jane Ellen Giamporcaro, L Jay Katz, Thomas W Samuelson Tags: Original Article Source Type: research
Efficacy and Tolerability of Travoprost 0.004%/Timolol 0.5% Fixed-Dose Combination for the Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Inadequately Controlled with Beta-Blocker Monotherapy.
Conclusion. Superior IOP control was achieved with TTFC in patients with OAG or OHT previously uncontrolled with beta-blockers. No new safety findings were identified. This trial is registered with ClinicalTrials.gov NCT02003391.
PMID: 28239491 [PubMed - in process] (Source: Journal of Ophthalmology)
Source: Journal of Ophthalmology - February 28, 2017 Category: Opthalmology Tags: J Ophthalmol Source Type: research
Sustained drug delivery for glaucoma: current data and future trends
Purpose of review:Sustained drug delivery has been recognized as a need for patients with ocular hypertension or glaucomatous optic neuropathy. Several sustained drug delivery systems and devices are currently on the horizon. This review aims to summarize initial results with these platforms, as reported in the literature, and also provide insight into their possible role in the glaucoma treatment paradigm.
Recent findings:Sustained drug delivery systems currently on the horizon include the topical bimatoprost ocular insert, travoprost and latanoprost punctal plugs, latanoprost-eluting contact lenses, bimatoprost and trav...
Source: Current Opinion in Ophthalmology - February 28, 2017 Category: Opthalmology Tags: GLAUCOMA: Edited by Donald L. Budenz Source Type: research
Pharmacokinetics and Safety of Travoprost 0.004% Ophthalmic Solution Preserved with Polyquad in Pediatric Patients with Glaucoma
Journal of Ocular Pharmacology and Therapeutics , Vol. 0, No. 0. (Source: Journal of Ocular Pharmacology and Therapeutics)
Source: Journal of Ocular Pharmacology and Therapeutics - February 23, 2017 Category: Opthalmology Source Type: research
The effects of selective laser trabeculoplasty and travoprost on circadian intraocular pressure fluctuations: A randomized clinical trial
Background: To compare the effect of selective laser trabeculoplasty (SLT) and travoprost on 24-hour IOP fluctuations in primary open-angle glaucoma (POAG) and normal-tension glaucoma (NTG).
Methods: Sixty eyes were included. Sixteen and 14 eyes of POAG patients were randomized to receive 360° SLT or 0.004% travoprost, respectively. Fourteen and 16 eyes of NTG patients were randomized to receive either SLT or travoprost, respectively. The 24-hour IOP data were collected before treatment and 6 to 8 weeks after treatment. IOP was measured at 2 hours intervals in the sitting position during daytime (9 AM to 7 PM) and in t...
Source: Medicine - February 1, 2017 Category: Internal Medicine Tags: Research Article: Clinical Trial/Experimental Study Source Type: research
Molecules, Vol. 22, Pages 217: A Novel Convergent Synthesis of the Potent Antiglaucoma Agent Tafluprost
Tafluprost (AFP-168, 5) is a unique 15-deoxy-15,15-difluoro-16-phenoxy prostaglandin F2 α (PGF2α) analog used as an efficacious ocular hypotensive agent in the treatment of glaucoma and ocular hypertension, as monotherapy, or as adjunctive therapy to β-blockers. A novel convergent synthesis of 5 was developed employing Julia–Lythgoe olefination of the structurally advanced prostag landin phenylsulfone 16, also successfully applied for manufacturing of pharmaceutical grade latanoprost (2), travoprost (3) and bimatoprost (4), with an aldehyde ω-chain synthon 17. The use of the same prostaglandin phenylsulfone 16, as a ...
Source: Molecules - January 30, 2017 Category: Chemistry Authors: Ma łgorzata Krupa Micha ł Chodyński Anna Ostaszewska Piotr Cmoch Iwona Dams Tags: Article Source Type: research
